Trump accelerates psychedelic research

In a significant policy shift, President Trump has ordered federal agencies to fast-track the clinical evaluation of psychedelic treatments for mental health conditions.

The executive order specifically highlights ibogaine, a drug currently banned under the federal government's most restrictive category but championed by figures like Joe Rogan.

The administration plans to allocate $50 million toward research focusing on the efficacy of these substances for combat veterans.

While some medical experts express caution regarding safety risks, the move has been welcomed by advocates seeking alternatives to traditional therapies.